French researchers found no significant difference in overall survival among 418 patients with acute myeloid leukemia who received either a donor lymphocyte infusion or a second allogeneic hematopoietic cell transplant, according to a study in the journal JAMA Oncology. The study also showed improved survival outcomes among those in complete remission and those who had prior chronic graft-versus-host disease.
Takeda's Ninlaro, or ixazomib, reportedly met its primary endpoint of extending progression-free survival as a single-agent maintenance therapy versus placebo in 656 multiple myeloma patients who had undergone induction therapy supported by high-dose therapy and an autologous stem cell transplant. Data from the Phase III TOURMALINE-MM3 trial will be submitted to regulatory agencies and will be presented at the American Society of Hematology's annual meeting later this year.
Israel-based medical devices startup Sight Diagnostics has released in Europe the OLO point-of-care blood diagnostics system, which allows AI-powered blood testing to be done in a doctor's office. The system, which the company hopes to get FDA approval for next year, digitizes blood into specifically colored microscope images and determines and counts blood cell types using proprietary machine vision algorithms.
UK researchers found Ebola survivors from Sierra Leone had lingering psychiatric and neurological problems, including depression, anxiety, debilitating migraines, nerve pain and strokes. The findings, based on more than 300 Ebola survivors, were published in the journal Emerging Infectious Diseases.
GlaxoSmithKline's investigational drug tafenoquine was found to be generally safe, effective and well-tolerated among malaria patients 16 and older, with data indicating the regimen induced a statistically significant treatment effect for Plasmodium vivax malaria, based on briefing documents the FDA disclosed before an advisory committee meeting. However, FDA researchers did note some concerns regarding the drug's safety in patients with anemia.
A seven-year international study that evaluated contemporary protease inhibitors' contribution to cardiovascular disease risk in treatment-naive adults with HIV found that Janssen's Prezista, or darunavir, was linked to progressively increasing risk of CVD compared to Bristol-Myers Squibb's Reyataz, or atazanavir. The findings, consisting of data from 49,709 participants in 11 cohorts in the US, Australia and Europe, were reported in the journal The Lancet HIV.
Researchers assessed 200 older male patients, ages 54 to 73, with moderate to severe hemophilia to establish the prevalence of cardiovascular disease and risk factors. Findings revealed that cardiovascular disease risk factors were common in this group, with nearly a third being obese, 50% of the group having dyslipidemia and hypertension, and only 36% of hypertensive patients taking antihypertensive medication, according to the study in the journal Blood Advances.
American Renal Associates has entered a three-year network agreement with UnitedHealthcare that will take effect Aug. 1. ARA will pay $32 million and be required to adopt certain procedures and share information with UnitedHealthcare, whose plan participants will be able to access ARA's dialysis clinics.
Scientists say they've developed a way to pinpoint risk of developing acute myeloid leukemia years before the onset of symptoms, according to a report in the journal Nature. The researchers sequenced DNA from the blood of 124 patients with AML and 676 people who did not have AML or a related cancer, evaluated data from AML-associated genes, and found certain mutations were more common in those who developed AML.
DNA copy-number profiles in circulating cell-free DNA have potential as a biomarker of active disease in melanoma patients, a study shows. The researchers note that "longitudinal analysis of copy-number profiles as an early marker of relapsed disease is warranted."
- Page 1